US SARS-CoV-2 Seroprevalence High Based on Blood Donations
The combined severe acute respiratory syndrome coronavirus 2 seroprevalence from infection or vaccination reached an estimated 94.7% in December 2021.
COVID19
Neurological Symptoms Persist After SARS-CoV-2 Infection
Only one-third of individuals with neurologic symptoms following SARS-CoV-2 infection report complete symptom resolution by 6 months.
Perioperative SARS-CoV-2 Testing Recommendations Updated
The recommendations for perioperative testing for SARS-CoV-2 have been updated by the American Society of Anesthesiologists and the Anesthesia Patient Safety Foundation.
Study Compares Baricitinib to Dexamethasone for COVID-19
For hospitalized patients with COVID-19 requiring supplemental oxygen, baricitinib plus remdesivir and dexamethasone plus remdesivir result in similar mechanical ventilation-free survival by day 29, but adverse events occur more frequently with dexamethasone.
Chronically Ill WTC Responders Face Higher Risk for Severe COVID-19
WTC responders who suffer from exposure-related chronic conditions also face an increased risk for worse COVID-19 outcomes, including long COVID.
Mixed Results for Paxlovid in Standard Risk Patients With COVID-19
The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.
Veterans Report Low Rates of Adverse Events With mRNA Vaccines
Adverse events associated with COVID-19 mRNA vaccines are low but are slightly higher at 42 days for those receiving Pfizer-BioNTech.
Vaccination Offers Partial Protection for Postacute Phase of COVID-19
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) offers partial protection in the postacute phase of the disease.
Burden of Persistent Symptoms High After COVID-19 Infection
A high burden of persistent symptoms is observed in persons after COVID-19, but no specific causes of symptoms of PASC have been identified.
CDC Issues Guidance on COVID-19 Rebound After Paxlovid Treatment
Recent case reports suggest that some patients treated with Paxlovid may have a recurrence of COVID-19 symptoms 2 to 8 days after completing the 5-day course.
- Loading...
Loading...
Next post in General Medicine
Loading... 
Loading...